Revenues of $2.19 billion, up 4% sequentially and down 1% year-over-yearNet Income of $108 million, or $0.29 per shareAdjusted EBITDA* of $252 millionCash flow from operations ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Dividend stocks are thriving as rates drop. Explore Kiplinger's top picks for high returns, low risk, and steady growth.